Budros Ruhlin & Roe Inc. lifted its position in UnitedHealth Group (NYSE:UNH) by 11.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,277 shares of the healthcare conglomerate’s stock after purchasing an additional 228 shares during the quarter. Budros Ruhlin & Roe Inc.’s holdings in UnitedHealth Group were worth $502,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Capital International Investors grew its holdings in UnitedHealth Group by 399.3% during the third quarter. Capital International Investors now owns 4,132,602 shares of the healthcare conglomerate’s stock worth $809,370,000 after acquiring an additional 3,304,902 shares during the period. Jennison Associates LLC grew its holdings in UnitedHealth Group by 146.0% during the third quarter. Jennison Associates LLC now owns 5,541,977 shares of the healthcare conglomerate’s stock worth $1,085,396,000 after acquiring an additional 3,289,470 shares during the period. Egerton Capital UK LLP acquired a new stake in UnitedHealth Group during the fourth quarter worth about $368,905,000. Arrowstreet Capital Limited Partnership grew its holdings in UnitedHealth Group by 22.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,323,180 shares of the healthcare conglomerate’s stock worth $953,088,000 after acquiring an additional 792,527 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in UnitedHealth Group by 11.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 5,013,564 shares of the healthcare conglomerate’s stock worth $1,105,290,000 after acquiring an additional 512,182 shares during the period. Hedge funds and other institutional investors own 86.78% of the company’s stock.
In related news, Director Kenneth Irwin Shine sold 202 shares of UnitedHealth Group stock in a transaction that occurred on Thursday, April 19th. The stock was sold at an average price of $237.42, for a total transaction of $47,958.84. Following the transaction, the director now owns 28,948 shares in the company, valued at $6,872,834.16. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director William C. Ballard, Jr. sold 10,000 shares of UnitedHealth Group stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $246.38, for a total value of $2,463,800.00. Following the transaction, the director now owns 76,637 shares in the company, valued at approximately $18,881,824.06. The disclosure for this sale can be found here. Insiders sold 77,019 shares of company stock worth $17,879,133 over the last ninety days. Corporate insiders own 0.89% of the company’s stock.
Several research firms recently commented on UNH. Zacks Investment Research raised UnitedHealth Group from a “hold” rating to a “buy” rating and set a $267.00 target price on the stock in a report on Saturday, January 20th. Piper Jaffray reaffirmed a “buy” rating and set a $270.00 target price on shares of UnitedHealth Group in a report on Wednesday. Sanford C. Bernstein set a $275.00 target price on UnitedHealth Group and gave the stock a “buy” rating in a report on Wednesday. Royal Bank of Canada reaffirmed a “buy” rating on shares of UnitedHealth Group in a report on Wednesday. Finally, Oppenheimer raised their target price on UnitedHealth Group from $260.00 to $276.00 and gave the stock an “outperform” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $251.13.
Shares of NYSE:UNH opened at $235.06 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.73 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $228,136.20, a PE ratio of 23.34, a PEG ratio of 1.36 and a beta of 0.77. UnitedHealth Group has a 1 year low of $166.65 and a 1 year high of $250.79.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.91 by $0.13. The firm had revenue of $55.19 billion for the quarter, compared to analyst estimates of $54.90 billion. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.37 earnings per share. research analysts anticipate that UnitedHealth Group will post 12.61 EPS for the current fiscal year.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.